Delayed autologous stem cell transplantation following cardiac transplantation experience in patients with cardiac amyloidosis.
Adult
Aged
Amyloidosis
/ complications
Cardiomyopathies
/ complications
Case-Control Studies
Combined Modality Therapy
Female
Follow-Up Studies
Heart Transplantation
/ mortality
Humans
Male
Middle Aged
Prognosis
Retrospective Studies
Stem Cell Transplantation
/ mortality
Survival Rate
Time-to-Treatment
/ statistics & numerical data
Transplantation, Autologous
Treatment Outcome
autotransplantation
bone marrow/hematopoietic stem cell transplantation
cardiovascular disease
clinical research/practice
heart failure/injury
heart transplantation/cardiology
stem cells
Journal
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
ISSN: 1600-6143
Titre abrégé: Am J Transplant
Pays: United States
ID NLM: 100968638
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
23
12
2018
revised:
30
04
2019
accepted:
08
05
2019
pubmed:
4
6
2019
medline:
5
9
2020
entrez:
2
6
2019
Statut:
ppublish
Résumé
This study sought to retrospectively investigate the outcomes of patients with light-chain amyloidosis (AL) with advanced cardiac involvement who were treated with a strategy of heart transplantation (HT) followed by delayed autologous stem cell transplantation (ASCT) at 1-year posttransplant. Patients with AL amyloidosis with substantial cardiac involvement have traditionally had very poor survival (eg, several months). A few select centers have reported their outcomes for HT followed by a strategy of early ASCT (ie, 6 months) for CA. The outcomes of patients undergoing a delayed strategy have not been reported. All patients with AL amyloidosis at a single institution undergoing evaluation for HT from 2004-2018 were included. Retrospective analyses were performed. Sixteen patients underwent HT (including two combined heart-kidney transplant) for AL amyloidosis. ASCT was performed in a total of nine patients to date at a median 13.5 months (12.8-32.9 months) post-HT. Survival was 87.5% at 1 year and 76.6% at 5 years, comparable to institutional outcomes for nonamyloid HT recipients. In addition to these 16 patients, two patients underwent combined heart-lung transplantation. A strategy of delayed ASCT 1-year post-HT for patients with AL amyloidosis is feasible, safe, and associated with comparable outcomes to those undergoing an earlier ASCT strategy.
Identifiants
pubmed: 31152491
doi: 10.1111/ajt.15487
pii: S1600-6135(22)09274-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2900-2909Informations de copyright
© 2019 The American Society of Transplantation and the American Society of Transplant Surgeons.
Références
Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32(1):45-59.
Sperry BW, Ikram A, Hachamovitch R, et al. Efficacy of chemotherapy for light-chain amyloidosis in patients presenting with symptomatic heart failure. J Am Coll Cardiol. 2016;67(25):2941-2948. https://doi.org/10.1016/j.jacc.2016.03.593.
Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation. 2017;135(14):1357-1377. https://doi.org/10.1161/circulationaha.116.024438.
Grogan M, Gertz M, McCurdy A, et al. Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic Experience. World J Transplant. 2016;6(2):380-388. https://doi.org/10.5500/wjt.v6.i2.380.
Gilstrap LG, Niehaus E, Malhotra R, et al. Predictors of survival to orthotopic heart transplant in patients with light chain amyloidosis. J Heart Lung Transplant. 2014;33(2):149-156. https://doi.org/10.1016/j.healun.2013.09.004.
Davis MK, Kale P, Liedtke M, et al. Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era. Am J Transplant. 2015;15(3):650-658. https://doi.org/10.1111/ajt.13025.
Kristen AV, Kreusser MM, Blum P, et al. Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era. J Heart Lung Transplant. 2018;37(5):611-618. https://doi.org/10.1016/j.healun.2017.11.015.
Estep JD, Cordero-Reyes AM, Bhimaraj A, et al. Percutaneous placement of an intra-aortic balloon pump in the left axillary/subclavian position provides safe, ambulatory long-term support as bridge to heart transplantation. JACC Heart Fail. 2013;1(5):382-388. https://doi.org/10.1016/j.jchf.2013.06.002.
Organ Procurement and Transplantation Network/United Network for Organ Sharing Thoracic Organ Transplantation Committee. Public comment proposal to modify the Adult Heart Allocation System. https://optn.transplant.hrsa.gov/media/1921/thoracic_adult_heart_allocation_modification_20160815.pdf. Accessed May 2019.